FDA Congressional Relations, Internal Structure May Change With Sharfstein Exit
This article was originally published in The Tan Sheet
Executive Summary
The departure of Principal Deputy Commissioner Josh Sharfstein provides FDA an opportunity to take stock of its relationship with Congress and to re-evaluate its organizational structure.